IMUX on Nasdaq

IMMUNIC, INC.

American pharmaceutical preparations company based in New York. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerIMUX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address1200 Avenue Of The Americas, Suite 200, New York, X1 100363
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300R5T12FW5MEQB202
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 37493612

See how the biggest companies compare on our leaderboards

Immunic, Inc. (“Immunic," “we,” “us,” “our” or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany. We had 92 employees as of February 1, 2026.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$103.2M in 2025+179% since 2019
-$150.0M-$100.0M-$50.0M02019: -$37.0M-$37.0M20192020: -$49.0M-$49.0M2020+32%2021: -$91.7M-$91.7M2021+87%2022: -$119.5M-$119.5M2022+30%2023: -$99.2M-$99.2M2023−17%2024: -$98.1M-$98.1M2024−1%2025: -$103.2M-$103.2M2025+5%
Net income5678910-$97.2M in 2025+178% since 2019
-$150.0M-$100.0M-$50.0M02019: -$34.9M-$34.9M20192020: -$44.0M-$44.0M2020+26%2021: -$92.9M-$92.9M2021+111%2022: -$120.4M-$120.4M2022+30%2023: -$93.6M-$93.6M2023−22%2024: -$100.5M-$100.5M2024+7%2025: -$97.2M-$97.2M2025−3%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$82.0M$80.0M
General and administrative$21.2M$18.0M
Total operating expenses$103.2M$98.1M
Loss from operations-$103.2M-$98.1M
Interest income$1.0M$3.4M
Change in fair value of the tranche rights$0-$4.8M
Other income (expense), net$5.0M-$1.0M
Total other income (expense), net$6.1M-$2.5M
Net loss-$97.2M-$100.5M
Net loss per share, basic (in usd per share)-$0.62-$1.00
Net loss per share, diluted (in usd per share)-$0.62-$1.00
Weighted-average common shares outstanding, basic (in shares)155.7M shares100.2M shares
Weighted-average common shares outstanding, diluted (in shares)155.7M shares100.2M shares

Compare IMMUNIC, INC. with another company

Leadership

Who has led IMMUNIC, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Terence E. Winters2014–2017
  2. Russell J. Cox2018–2019
  3. Daniel Vitt2019–2026
  4. Erik Lundgren2026–now

Chair

  1. Terence E. Winters2014–2017
  2. Duane Nash2020–now

President

  1. Duane Nash2016–2019
  2. Daniel Vitt2019–2024
  3. Jason Tardio2024–now

Chief financial officer

  1. Sanjay S. Patel2019
  2. Glenn Whaley2022–now

Chief operating officer

  1. Manfred Groeppel2019–2021
  2. Jason Tardio2024–now
201520202025
Board members and other officers (35)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerHELLA KOHLHOF named Oct 18, 2022 to Mar 4, 202655
  • Executive OfficerINDERPAL SINGH named Jan 19, 2024 to Mar 4, 202655
  • Executive OfficerPATRICK WALSH named Oct 18, 2022 to Mar 4, 202655
  • Executive OfficerInderpal Maria Singh named Oct 18, 202256
  • DirectorJOERG NEERMAN named Mar 4, 202655
  • DirectorTHORVALD NAGEL named Mar 4, 202655
  • DirectorJorg Neermann named Jan 19, 202457
  • DirectorMaria Tornsen named Jan 19, 202457
  • DirectorJorg Neerman named Oct 18, 202256
  • DirectorMonika Maria Tornsen named Oct 18, 202256

Former names

  • VITAL THERAPIES INCFeb 18, 2004 to Apr 10, 20193

Timeline

  1. Jun 1, 2026New chief executive Erik Lundgren becomes CEO13
  2. Apr 22, 2019New chief executive Daniel Vitt becomes CEO14
  3. Jan 4, 2018New chief executive Russell J. Cox becomes CEO15
  4. Apr 23, 2014New chief executive Terence E. Winters becomes CEO16
  5. Jan 13, 2004Founded IMMUNIC, INC. is founded2

Filings

330 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 80 major events, 119 insider forms, 65 large holders, 3 private raises, 42 other. The latest 20:

  1. Oct 1, 2026S-8 EDGAR
  2. Sep 18, 20264 EDGAR
  3. Sep 18, 20264 OWNERSHIP DOCUMENT EDGAR
  4. Sep 11, 20268-K EDGAR
  5. Sep 9, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 14, 2026SCHEDULE 13G EDGAR
  9. Aug 13, 2026SCHEDULE 13G/A EDGAR
  10. Aug 12, 2026S-8 EDGAR
  11. Aug 11, 202610-Q EDGAR
  12. Aug 11, 20268-K EDGAR
  13. Aug 10, 20264 EDGAR
  14. Aug 10, 20263 EDGAR
  15. Aug 6, 2026SCHEDULE 13G/A EDGAR
  16. Aug 4, 2026SCHEDULE 13G EDGAR
  17. Jul 16, 2026SCHEDULE 13G/A EDGAR
  18. Jul 14, 20268-K EDGAR
  19. Jul 7, 20264 EDGAR
  20. Jul 7, 20264 EDGAR

The 330 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 22 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 13, 2025Nash DuaneExecutive ChairmanBuy20,000$0.83$16.6KForm 4
Jun 5, 2025Tardio JasonPresident and COOBuy12,512$0.79$9.9KForm 4
Jun 5, 2025Tardio JasonPresident and COOBuy12,512$0.79$9.9KForm 4
Jun 5, 2025Neermann JoergDirectorBuy30,000$0.76$22.8KForm 4
Jun 4, 2025Vitt DanielDirectorBuy15,000$0.77$11.6KForm 4
Jun 4, 2025Vitt DanielDirectorBuy15,000$0.77$11.6KForm 4
Jun 4, 2025Neermann JoergDirectorBuy70,000$0.77$53.9KForm 4
Jun 3, 2025Whaley GlennChief Financial OfficerBuy45,000$0.71$31.9KForm 4
Jun 3, 2025Rudick Richard AlanDirectorBuy143,075$0.70$100.2KForm 4
Nov 12, 2024Rudick Richard AlanDirectorBuy87,300$1.15$100.4KForm 4
Feb 26, 2024Vitt DanielDirectorBuy14,000$1.31$18.3KForm 4
May 15, 2023Whaley GlennChief Financial OfficerBuy5,000$1.75$8.8KForm 4
Dec 14, 2022Neermann JoergDirectorBuy47,000$1.26$59.2KForm 4
Dec 13, 2022Neermann JoergDirectorBuy35,000$1.25$43.8KForm 4
Nov 23, 2022Neermann JoergDirectorBuy18,000$1.39$25.0KForm 4
Nov 22, 2022Vitt DanielDirectorBuy8,000$1.35$10.8KForm 4
Nov 7, 2022Whaley GlennChief Financial OfficerBuy5,000$1.50$7.5KForm 4
Jun 3, 2022Vitt DanielDirectorBuy5,000$3.10$15.5KForm 4
Jun 3, 2022Whaley GlennChief Financial OfficerBuy3,500$3.05$10.7KForm 4
May 12, 2022Muehler AndreasChief Medical OfficerBuy3,500$5.10$17.9KForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 17, 2026Raised $200 million in a private offering of equity Form D: 43 investors so far Form D
  2. Jan 4, 2024Raised $80 million in a private offering of equity Form D: $240 million offered in all Form D
  3. Oct 10, 2022Raised $60 million in a private offering of equity Form D: 14 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 55. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Aberdeen Group plc824,393$12.7M0.0%New
Bvf Inc/il765,295$11.8M0.3%New
Millennium Management LLC740,347$11.4M0.0%New
Avidity Partners Management LP669,941$10.3M1.6%New
Braidwell LP645,010$9.9M0.4%New
Laurion Capital Management LP610,326$9.4M0.7%New
Vanguard Capital Management LLC571,561$8.8M0.0%New
Jones Hill Capital LP539,814$8.3M1.8%New
Nantahala Capital Management, LLC501,292$7.7M0.2%New
Woodline Partners LP471,528$7.2M0.0%New
Soleus Capital Management, L.P.450,000$6.9M0.2%New
Propel Bio Management, LLC325,022$5.0M2.6%New
UBS Group AG175,756$2.7M0.0%New
Geode Capital Management, LLC170,675$2.6M0.0%New
683 Capital Management, LLC147,245$2.3M0.2%New
Adage Capital Partners Gp, L.l.c.139,860$2.1M0.0%New
BlackRock, Inc.132,791$2.0M0.0%New
Marshall Wace, Llp104,816$1.6M0.0%−848,150
Susquehanna International Group, Llp90,890$1.4M0.0%New
Jane Street Group, LLC89,687$1.4M0.0%New
Jefferies Financial Group Inc.84,900$1.3M0.0%New
Vanguard Fiduciary Trust Co82,029$1.3M0.0%New
Ikarian Capital, LLC67,464$1.0M0.2%New
Quadrature Capital Ltd37,786$580.8K0.0%New
Simplify Asset Management Inc.30,725$472.2K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83